‘Clear signal’: Medicare Part D denials may limit access to appropriate cancer drugs

One-fifth of cancer drugs initially denied coverage by Medicare Part D insurance plans ultimately received approval from independent reviewers after second-level appeal, according to study results.“This suggests that Part D plans may be making decisions that deny people with cancer access to potentially clinically appropriate medications,” lead author Youngmin Kwon, PhD, a